KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Dec 2024 value amounting to $7.3 million.

  • CRISPR Therapeutics AG's Gains from Investment Securities rose 47.01% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year increase of 16.79%. This contributed to the annual value of $7.3 million for FY2024, which is 1.17% up from last year.
  • As of FY2024, CRISPR Therapeutics AG's Gains from Investment Securities stood at $7.3 million, which was up 1.17% from $7.2 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Gains from Investment Securities registered a high of $7.3 million during FY2024, and its lowest value of $1.5 million during FY2022.
  • Over the past 3 years, CRISPR Therapeutics AG's median Gains from Investment Securities value was $7.2 million (recorded in 2023), while the average stood at $5.3 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Gains from Investment Securities fell by 25.95% in 2021 and then spiked by 382.68% in 2023.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Gains from Investment Securities stood at $2.2 million in 2020, then decreased by 25.95% to $1.6 million in 2021, then decreased by 7.65% to $1.5 million in 2022, then spiked by 382.68% to $7.2 million in 2023, then rose by 1.17% to $7.3 million in 2024.